

ARTICLE OPEN



Depdc5 deficiency exacerbates alcohol-induced hepatic steatosis via suppression of PPAR α pathway

Lin Xu^{1,2}, Xinge Zhang^{2,3}, Yue Xin^{2,3}, Jie Ma⁴, Chenyan Yang^{2,3}, Xi Zhang¹, Guoqing Hou¹, Xiaocheng Charlie Dong⁵, Zhaoli Sun⁶, Xiwen Xiong^{2,3} and Xuan Cao¹

© The Author(s) 2021

Alcohol-related liver disease (ALD), a condition caused by alcohol overconsumption, occurs in three stages of liver injury including steatosis, hepatitis, and cirrhosis. DEP domain-containing protein 5 (DEPDC5), a component of GAP activities towards Rags 1 (GATOR1) complex, is a repressor of amino acid-sensing branch of the mammalian target of rapamycin complex 1 (mTORC1) pathway. In the current study, we found that aberrant activation of mTORC1 was likely attributed to the reduction of DEPDC5 in the livers of ethanol-fed mice or ALD patients. To further define the *in vivo* role of DEPDC5 in ALD development, we generated *Depdc5* hepatocyte-specific knockout mouse model (*Depdc5*-LKO) in which mTORC1 pathway was constitutively activated through loss of the inhibitory effect of GATOR1. Hepatic *Depdc5* ablation leads to mild hepatomegaly and liver injury and protects against diet-induced liver steatosis. In contrast, ethanol-fed *Depdc5*-LKO mice developed severe hepatic steatosis and inflammation. Pharmacological intervention with Torin 1 suppressed mTORC1 activity and remarkably ameliorated ethanol-induced hepatic steatosis and inflammation in both control and *Depdc5*-LKO mice. The pathological effect of sustained mTORC1 activity in ALD may be attributed to the suppression of peroxisome proliferator activated receptor α (PPAR α), the master regulator of fatty acid oxidation in hepatocytes, because fenofibrate (PPAR α agonist) treatment reverses ethanol-induced liver steatosis and inflammation in *Depdc5*-LKO mice. These findings provide novel insights into the *in vivo* role of hepatic DEPDC5 in the development of ALD.

Cell Death and Disease (2021)12:710; <https://doi.org/10.1038/s41419-021-03980-6>

INTRODUCTION

Alcohol-related liver disease (ALD) encompasses a broad spectrum of progressive liver pathologies that range from simple steatosis to severe forms of liver injury, such as steatohepatitis, liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC) [1]. Since no effective therapies for end-stage ALD are currently available, there is a clinical need for better understanding of the pathogenesis of ALD and identification of therapeutic targets.

Mammalian target of rapamycin complex 1 (mTORC1) is a highly conserved protein kinase complex that regulates cell growth and metabolism in response to growth factor, nutrient abundance and cellular stress [2]. The tuberous sclerosis complex (TSC), consisting of TSC1, TSC2, and TBC1D7, is a major mediator of growth factor and cellular stress signaling to mTORC1. TSC acts as a GTPase-activating protein (GAP) for Rheb and serves as a negative regulator of mTORC1 signaling [3]. The GAP activities towards Rags 1 complex (GATOR1), which consists of DEP domain-containing protein 5 (DEPDC5), NPR2-like GATOR1 complex subunit (NPRL2), and NPR3-like GATOR1 complex subunit (NPRL3), is a pivotal negative regulator of mTORC1 activation in response to amino acids. GATOR1 prevents translocation of mTORC1 to its

active site at the lysosome membrane during amino acid insufficiency by acting as a GAP to keep Rag A/B in the inactive GDP state [4]. As a component of GATOR1 complex, DEPDC5 functions as a GAP for Rag A/B [4]. DEPDC5 was identified as a gene responsible for familial focal epilepsy [5, 6]. Germline homozygous knockout *Depdc5* rat and mouse models are embryonic lethal due to mTORC1 hyperactivation [7, 8]. Importantly, genetic variations in the *DEPDC5* locus were associated with hepatitis C virus (HCV)-induced fibrosis or HCC progression in humans [9, 10].

As one of the essential metabolic organs, the liver requires proper regulation of mTORC1 activity for maintaining homeostasis and preventing pathologies [11]. Disrupting mTORC1 through liver-specific deletion of regulatory-associated protein of mTOR (Raptor) in mice inhibits the sterol regulatory element-binding protein1 (SREBP1) target gene expression and suppresses liver fat accumulation in response to a high-fat and high-cholesterol diet feeding [12]. Surprisingly, activating mTORC1 through liver-specific deletion of *Tsc1* does not induce fat accumulation in the liver and even protects the liver against high-fat diet (HFD)-induced hepatic steatosis [13, 14]. A recent study has

¹Department of Medical Genetics, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China. ²School of Forensic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, PR China. ³Xinxiang Key Laboratory of Metabolism and Integrative Physiology, Xinxiang Medical University, Xinxiang, Henan 453003, PR China. ⁴Department of Human Anatomy & Histoembryology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453003, PR China. ⁵Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. ⁶Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ✉email: xwxiong@xxmu.edu.cn; caoxuan@hust.edu.cn

Edited by: A. Finazzi-Agrò

Received: 7 April 2021 Revised: 21 June 2021 Accepted: 22 June 2021

Published online: 15 July 2021

demonstrated that liver-specific *Depdc5* knockouts exhibit many phenotypes similar to *Tsc1* knockout mice, such as elevated inflammation and resistance to HFD-induced steatosis [15]. Although great progress has been made in unraveling how mTORC1 regulates the pathophysiology of nonalcoholic fatty liver disease (NAFLD), relatively little is known about the role of mTORC1 pathway in ALD. In this study, we aimed to examine the *in vivo* role of aberrant mTORC1 activation caused by *Depdc5* deletion in regulating pathogenesis of ALD.

MATERIALS AND METHODS

Human liver tissue samples

Control and alcoholic hepatitis (AH) human liver samples were obtained under the institutional review board protocol approved by Johns Hopkins University School of Medicine (Table S1).

Animal studies

The study was approved by the Institutional Animal Care and Use Committee of Xixiang Medical University, China. All animal procedures were performed in accordance with "Guide for the Care and Use of Laboratory Animals" published by the National Institutes of Health. Euthanasia was performed using compressed carbon dioxide (CO₂) from gas cylinders or cervical dislocation under anesthesia. Group allocation for the experiments was randomized and not blinded. Sample analyses were not blinded.

Depdc5 floxed mice (*Depdc5^{fllox/fllox}*), originated from the ES clone (Clone No. HEPD0734_3_G10), were provided by the CAM-SU Genomic Resource Center, Soochow University (Suzhou, China), one of the mutant ES cell repositories for Asian-Pacific research community in International Mouse Phenotyping Consortium (IMPC). The hepatocyte-specific *Depdc5* knockout mice were generated by crossing *Depdc5^{fllox/fllox}* mice with *Albumin (Alb)-Cre* mice.

Both 2–3-month-old male and female mice were used in generating mouse models of ALD. We generated two mouse ALD models in the current study: (1) Chronic-plus-binge ethanol feeding model (Gao-Binge model). The Gao-Binge ethanol feeding protocol as described previously [16]. (2) Lieber-DeCarli liquid diet feeding model (LD 5W model). Mice were fed a Lieber-DeCarli liquid diet containing 5% ethanol (v/v) or an isocaloric control diet for 5 weeks. Then, mice were euthanized without ethanol binge and, blood and liver tissues were collected.

For Torin 1 treatment, LoxP and *Depdc5*-LKO mice received daily *i.p.* injections of 20 mg/kg Torin 1 (dissolved in 20% *N*-methyl-2-pyrrolidone/40% PEG400/40% H₂O) or vehicle from the 6th day to the 10th day of ethanol diet feeding. On the 11th day morning, mice were injected with Torin 1 immediately after ethanol binge and were sacrificed 9 h later. For fenofibrate treatment, 3-month-old LoxP and LKO mice were fed 5% ethanol diet containing 0.02% fenofibrate for 10 days and then binged with ethanol at 8:00 am of the 11th day, and were sacrificed 9 h later. For adenovirus-mediated liver-specific gene knockdown, Ad-shGFP vs Ad-shRaptor adenoviruses were delivered via tail vein injection (1×10^9 pfu/mouse) into 3-month-old LoxP and LKO mice on the 1st day of ethanol diet feeding. Mice were binged with ethanol on the 11th day morning and were sacrificed 9 h later.

Adenovirus preparation

Ad-shRaptor and control Ad-shGFP vectors were generated using the pAdBLOCK-iT system (Invitrogen, USA). Adenoviruses were amplified in HEK293A cells and purified by CsCl gradient centrifugation. The adenoviruses were titered using an Adeno-XTM Rapid Titer kit (Takara Bio, China) according to the manufacturer's manual.

Western blot analysis

Protein extracts from hepatocytes or liver tissues were made in RIPA buffer supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and Roche cComplete protease inhibitor cocktail (Roche, Germany). Protein extracts were separated on an SDS-PAGE gel, transferred to nitrocellulose membranes, and blotted with the indicated primary antibodies at 4°C for overnight. Horseradish peroxidase (HRP)-conjugated secondary antibodies were given for 1 h. The immune complexes were detected using the ECL detection reagents (Beyotime, China). Band densitometries were obtained with ImageJ software. Detailed information of the primary antibodies used in this study is listed in Table S2.

Real-time RT-PCR analysis

Total RNAs were extracted from liver tissues using TRIzol reagent (Takara Bio, China) and converted into cDNAs using a cDNA synthesis kit (Vazyme, China). Real-time PCR analysis was performed using SYBR Green Master Mix (Vazyme, China) in ABI StepOnePlus Real-Time PCR system. Sequence information of the primers used in this study is listed in Table S3.

RNA sequencing

The total liver RNAs from alcohol-fed LoxP and *Depdc5*-LKO mice (3 biological replicates) were used for RNA-seq. The RNA-seq libraries were prepared by the Beijing Genomics Institute and sequenced using BGISEQ-500 platform. Genes that significantly and differentially expressed between LoxP and LKO mice were selected based on a fold change >2.0 and a *p*-value < 0.05, and subsequently analyzed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The original RNA-seq data have been submitted to the database of NCBI Sequence Read Archive under the accession number SUB9331871.

Histology

Liver tissues were fixed in 4% paraformaldehyde (PFA), embedded in paraffin and sectioned at a thickness of 5 μm. Sections were stained with hematoxylin-eosin (H&E) according to standard procedures. Immunohistochemistry (IHC) analysis for detecting oxidative stress (anit-4-HNE) and inflammation (anit-F4/80 and anti-MPO) was performed using IHC detection kit (ZSGB Bio, China) following manufacturer's manual. For Oil Red O staining, 4% PFA-fixed liver tissues were embedded in OCT, sectioned at 10 μm, and then stained with 0.5% Oil Red O according to standard procedures.

Transmission electron microscopy

Mouse liver tissues (~1 mm³) were fixed with 2% glutaraldehyde for 2 h, followed by 1% osmium tetroxide for 2 h. After dehydration and embedding in resin, ultra-thin sections (80 nm) were stained with uranyl acetate and lead citrate and analyzed in HT7800 transmission electron microscope (TEM) (Hitachi, Japan).

Biochemical analysis

Hepatic lipids were extracted with chloroform/methanol (2:1), as described previously [17]. Liver triglyceride (TG) levels were determined using triglyceride quantification kit (Sigma, USA) and normalized with liver tissue weights. Serum alanine aminotransferase (ALT) levels were analyzed using ALT assay kit (Nanjing Jiancheng, China).

Statistical analysis

All data are presented as mean ± SD. Using GraphPad Prism 8 software, data were analyzed by one-way analysis of variance between multiple groups, when appropriate, and by a two-tailed unpaired Student's *t*-test between two groups. *p* < 0.05 was considered as significant.

RESULTS

Deletion of hepatic *Depdc5* activates mTORC1 signaling and results in mild liver injury

Depdc5 floxed mice were crossed with *Albumin-Cre* mice to generate hepatocyte-specific *Depdc5* knockout mice (referred to as *Depdc5*-LKO mice, genotype: *Depdc5^{fllox/fllox}/Cre*) and control mice (referred to as LoxP, genotype: *Depdc5^{fllox/fllox}*) (Fig. 1A, B). Deletion of *Depdc5* in the liver of LKO mice was confirmed at both mRNA and protein levels (Fig. 1C). Liver-weight-to-body-weight ratios were significantly higher in *Depdc5*-LKO mice compared to LoxP mice (Fig. 1D, E). H&E staining of liver sections revealed that *Depdc5*-LKO mice had specific enlargement of pericentral zone 3 hepatocytes (Fig. 1H, I). *Depdc5*-LKO mice had a significant elevation of serum ALT level, indicating a mild liver damage caused by *Depdc5* ablation (Fig. 1F). Unexpectedly, the enlarged liver observed in *Depdc5*-LKO mice cannot be associated with hepatic steatosis, because *Depdc5*-LKO mice exhibited even slightly reduced liver triglyceride levels compared to LoxP mice (Fig. 1G). To further evaluate the effect of *Depdc5* deficiency on hepatic lipid metabolism, we challenged *Depdc5*-LKO mice with a




Fig. 1 Hepatocyte-specific *Depdc5* deletion induces upregulation of mTORC1 activity and mild liver injury. Two-month-old LoxP mice and *Depdc5*-LKO mice were subjected to the following analyses. **A**, **B** The strategy for creating *Depdc5* hepatocyte-specific knockout mice (**A**) used in the current study and a representative gel electrophoresis image for genotyping (**B**). **C** Western blot and qPCR analyses of DEPDC5 in the livers of control LoxP and LKO mice ($n = 4/\text{group}$). **D**, **E** Body weights (**D**) and liver-weight-to-body-weight ratios (**E**) of LoxP and LKO mice ($n = 5/\text{group}$). **F**, **G** Serum ALT (**F**) and hepatic TG (**G**) measurements of LoxP and LKO mice ($n = 5/\text{group}$). **H** Representative H&E images of liver sections from LoxP and LKO mice; the rectangular boxed areas in upper panels (100 \times) are magnified as shown in lower panels (400 \times). **I** Calculation of the cross-sectional area of zone 3 hepatocytes by ImageJ. **J** Western blot analysis of liver lysates from overnight fasting or 4 h refeeding LoxP and LKO mice are shown for the indicated phospho-(P) and total proteins. **K** Quantification of band intensities of phosphorylated proteins normalized to total proteins in (**J**). Data are presented as mean \pm SD. * $p < 0.05$. In (**K**), * $p < 0.05$ vs Fasting LoxP; # $p < 0.05$ vs Refeeding LoxP. Scale bars: (**H**) upper, 200 μm ; (**H**) lower, 50 μm .

HFD (60% kcal fat). Interestingly, *Depdc5*-LKO mice exhibited protection from HFD-induced hepatic steatosis (Fig. S1A–D). Hepatic deletion of *Depdc5* led to sustained activation of mTORC1 signaling even under fasting state, as shown by increased expression of P-S6K1 (Thr389) and P-S6 (Ser235/236) (Fig. 1J, K). Since constitutive activation of mTORC1 is known to suppress the activity of AKT secondary to feedback inhibition of activated S6K onto insulin receptor substrate 1 (IRS1), we observed that hepatic AKT phosphorylation at Ser473 and Thr308 was suppressed in both fasting and refeeding states in *Depdc5*-LKO mice (Fig. 1J, K).

Hepatic DEPDC5 is downregulated by chronic ethanol consumption

To test whether DEPDC5 contributes to alcohol-induced mTORC1 activation in the liver, we then determined hepatic DEPDC5 expression in two well-established mouse models of ALD, the chronic-plus-binge ethanol feeding model (Gao-Binge model) [16] and the Lieber-DeCarli ethanol diet feeding model (mice fed a 5% ethanol diet for 5 weeks, referred to as LD 5W model). As expected, ethanol administration by either approach led to a robust activation of mTORC1 signaling in the liver

(Fig. 2A–D). In both ALD models, hepatic DEPDC5 protein levels were remarkably reduced in ethanol-treated mice compared to their isocaloric pair-fed controls (Fig. 2A–D). Interestingly, the reduced DEPDC5 protein levels were not due to the suppression of *Depdc5* transcription as evidenced by unchanged *Depdc5* mRNA levels in the liver tissues of mice treated with ethanol by either approach (Fig. 2E, F). A recent study has revealed that kelch-like family member 22 (KLHL22), an adaptor protein of the CUL3–RBX1–KLHL22 E3 ligase complex, regulates the ubiquitination and degradation of DEPDC5 in response to amino acid availability [18]. We hypothesized that the decrease of hepatic DEPDC5 protein in ALD mice was due to enhanced degradation mediated by KLHL22. Indeed, a robust increase of hepatic KLHL22 expression was observed in both mouse models of ALD (Fig. 2A–F). To gain clinical evidence for the relationship among mTORC1 signaling, DEPDC5, and KLHL22, we analyzed their protein levels in the liver samples from healthy controls and patients with AH. As expected, we found that phospho-S6 (S235/236) and KLHL22 protein levels were markedly elevated, whereas DEPDC5 protein levels were significantly reduced in the liver tissues from AH patients compared to those from controls (Fig. 2G, H).




Fig. 2 Chronic alcohol consumption reduces DEPDC5 protein while activates mTORC1 signaling in the liver. Two–three-month-old LoxP and *Depdc5*-LKO mice were subjected to chronic-plus-binge ethanol feeding (Gao-Binge model) or Lieber-DeCarli liquid diet containing 5% ethanol feeding for 5 weeks (LD 5W model). **A, B** Western blot (**A**) and quantification (**B**) analyses of hepatic mTORC1 signaling, DEPDC5, and KLHL22 in mice treated with Gao-Binge ethanol feeding. **C, D** Western blot (**C**) and quantification (**D**) analyses of hepatic mTORC1 signaling, DEPDC5, and KLHL22 in mice treated with LD 5W ethanol feeding. **E, F** qPCR analysis of mRNA expression of *Depdc5* and *Klhl22* genes in the livers of mice treated with Gao-Binge ethanol feeding (**E**) or LD 5W ethanol feeding (**F**) and their corresponding pair-fed controls ($n = 4\text{--}5/\text{group}$). **G, H** Western blot and quantification analyses of mTORC1 signaling, DEPDC5, and KLHL22 in the liver samples of normal controls and AH patients. Data are presented as mean \pm SD. * $p < 0.05$.

Hepatic loss of *Depdc5* exacerbates alcohol-induced steatosis

Chronic activation of mTORC1 signaling in hepatocytes protects against diet-induced hepatic steatosis [13–15]. However, the consequences of mTORC1 signaling hyperactivation in the development of ALD are still unknown. To investigate the role of hepatic *Depdc5* deletion mediated hyperactivation of mTORC1

in ALD pathogenesis, *Depdc5*-LKO, and control LoxP mice were subjected to Gao-Binge ethanol feeding. *Depdc5* ablation and ethanol exposure synergistically activated mTORC1 signaling and further inhibited AKT activity through feedback loop in the liver (Fig. 3A, B). Moreover, ethanol-fed *Depdc5*-LKO mice exhibited severely impaired liver autophagy, as demonstrated by dramatic




Fig. 3 Hepatic deletion of *Depdc5* provokes ethanol-induced liver steatosis. Two–three-month-old LoxP and *Depdc5*-LKO mice were subjected to Gao-Binge ethanol feeding. **A, B** Liver lysates were subjected to western blot (**A**) and quantification (**B**) analyses to examine mTORC1 signaling and AKT phosphorylation. **C–E** Liver-weight-to-body-weight ratios (**C**), serum ALT levels (**D**), and liver TG levels (**E**) were determined ($n = 5–6/\text{group}$). **F** Liver sections were analyzed through H&E and Oil Red O staining (200 \times). Data are presented as mean \pm SD. * $p < 0.05$ vs PF LoxP; # $p < 0.05$ vs AF LoxP. Scale bars, 100 μm .

accumulation of p62 and reduced LC3-II protein (Fig. S2A). In addition, the expression of ER stress markers (CHOP, BiP, ATF4, XBP1s, and ATF6) was significantly elevated in the liver tissues of ethanol-fed *Depdc5*-LKO mice (Fig. S2B). Gao-Binge ethanol-fed *Depdc5*-LKO mice exhibited the most dramatic increase of liver-weight-to-body-weight ratios and had the highest serum ALT levels among the four groups of mice we studied (Fig. 3C, D). Surprisingly, in contrast to what we observed in HFD feeding experiment, Gao-Binge ethanol feeding remarkably elevated hepatic triglyceride levels in *Depdc5*-LKO mice compared to LoxP mice (Fig. 3E, F). We next examined whether hepatic *Depdc5* deficiency contributes to the development of alcohol-induced steatosis in another ALD mouse model, LD 5W model. Notably, we also observed increased liver-weight-to-body-weight ratios, liver triglyceride contents, and serum ALT levels in *Depdc5*-LKO mice compared to LoxP mice, indicating *Depdc5* deletion-mediated mTORC1 activation worsens the hepatic steatosis induced by ethanol (Fig. S3A–D).

Deletion of hepatic *Depdc5* aggravates alcohol-induced oxidative stress and inflammation

In addition to inducing lipid dysregulation, mTORC1 hyperactivation also results in other liver abnormalities, e.g., oxidative stress and inflammation [15, 19]. Indeed, ethanol-fed *Depdc5*-LKO mice had higher levels of oxidative stress in the liver, as indicated by an elevation of lipid peroxidation markers, 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) (Fig. 4A, B). Moreover, ethanol-fed *Depdc5*-LKO mice had significantly more macrophages (F4/80 positive) and neutrophils (MPO positive) in the liver than LoxP mice, indicating hyperactivation of mTORC1 signaling worsened ethanol-induced hepatic inflammation (Fig. 4A, C, D). Consistently, the mRNA expression of proinflammatory cytokines including *Il6*, *Il1b*, *Ccl2*, *Tnf* was also highly induced in the liver tissues of ethanol-fed *Depdc5*-LKO mice (Fig. 4E). To investigate whether hepatic deletion of *Depdc5* aggravates ethanol-induced liver fibrosis, we next investigate the expression of fibrogenic markers.

Unexpectedly, no significant alterations in hepatic expression of fibrosis-related genes were noted in ethanol-fed LoxP and *Depdc5*-LKO mice (Fig. S4A, B). Sirius Red staining also revealed comparable deposition of collagen contents between both genotypes of mice fed an ethanol diet (Fig. S4C).

Pharmacologic inhibition of mTOR rescues ethanol-induced hepatic steatosis and inflammation in *Depdc5*-LKO mice

To test whether the ethanol-induced liver pathologies in *Depdc5*-LKO mice were mainly due to mTORC1 activation, we took advantage of adenoviral shRNA expression system to create a relatively liver-specific knockdown of *Raptor*, which is the key scaffolding protein of the mTORC1 complex [2]. Ad-shRaptor markedly decreased hepatic RAPTOR protein levels and suppressed mTORC1 signaling activity (Fig. S5A). *Raptor* knockdown significantly reversed the ethanol-induced hepatic steatosis caused by *Depdc5* deletion (Fig. S5B, D, E). In addition, *Raptor* knockdown slightly ameliorated liver injury and inflammation in *Depdc5*-LKO mice as well (Fig. S5C, F–H). Surprisingly, LoxP mice that received Ad-shRaptor had elevated serum ALT levels and increased hepatic immune cells infiltration compared to LoxP mice that received Ad-shGFP (Fig. S5C, F–H), which is consistent with the previous study that hepatocyte-specific deletion of *Raptor* results in liver damage and a marked enhancement of hepatocarcinogenesis [20].

Ad-shRaptor-mediated *Raptor* knockdown led to persistent inactivation of mTORC1 and exacerbated ethanol-induced liver injury. We took advantage of Torin 1, an ATP-competitive mTOR inhibitor that inhibits mTORC1 signaling [21], to modestly suppress mTORC1 activity in ethanol-fed *Depdc5*-LKO and LoxP mice. Torin 1 treatment remarkably blocked the phosphorylation of S6 and AKT (Ser473), whereas induced the phosphorylation of AKT (Thr308) due to inhibition of the mTORC1-dependent negative feedback loop (Fig. 5A, B). After Torin 1 administration, liver-weight-to-body-weight ratios, liver triglyceride levels and serum ALT levels showed dramatic recovery, indicating that




Fig. 4 Hepatic ablation of *Depdc5* aggravates ethanol-induced oxidative stress and inflammation in the liver. Two–three-month-old LoxP and *Depdc5*-LKO mice were subjected to Gao-Binge ethanol feeding. **A** IHC analysis of 4-HNE, F4/80, and MPO in liver sections (200 \times , $n = 3$ –4/group). **B** Hepatic MDA measurements ($n = 4$ –5/group). **C**, **D** Quantification of F4/80-positive cells (**C**) and MPO-positive cells (**D**) shown in (**A**). **E** qPCR analysis of hepatic mRNA expression of inflammation-related genes ($n = 5$ /group). Data are presented as mean \pm SD. * $p < 0.05$ vs PF LoxP; # $p < 0.05$ vs AF LoxP. Scale bars, 100 μ m.

sustained hepatic mTORC1 activation is indeed the major cause of hepatic steatosis observed in *Depdc5*-LKO mice (Fig. 5C–F). In addition, we also analyzed the effect of Torin 1 administration on hepatic inflammation. Analysis of F4/80 and myeloperoxidase (MPO) staining demonstrated that Torin 1 treatment markedly reduced the number of macrophages and neutrophils in the liver tissues of both genotypes of mice (Fig. 5G–I).

Hepatic loss of *Depdc5* suppresses peroxisome proliferator activated receptor α (PPAR α) activity and damages mitochondria

To delineate the molecular mechanisms of Gao-Binge ethanol feeding-induced hepatic steatosis in *Depdc5*-LKO mice, we assessed the mRNA expression of key genes involved in the main pathways in hepatic lipid metabolism. Surprisingly, Gao-Binge




Fig. 5 Torin 1 administration rescues Gao-Binge ethanol feeding-induced liver abnormalities in Depdc5-LKO mice. Three-month-old male LoxP and Depdc5-LKO mice were subjected to Gao-Binge ethanol feeding. **A**, **B** Liver lysates were subjected to western blot (**A**) and quantification (**B**) analyses to examine mTORC1 signaling and AKT phosphorylation. **C–E** Liver-weight-to-body-weight ratios (**C**), serum ALT levels (**D**) and liver TG levels (**E**) were determined ($n = 4/\text{group}$). **F** Liver sections were analyzed through H&E and Oil Red O staining (200 \times). **G** Hepatic macrophages and neutrophils were examined by IHC staining (200 \times) with anti-F4/80 and anti-MPO antibodies ($n = 4/\text{group}$). **H**, **I** Quantification of F4/80-positive cells (**H**) and MPO-positive cells (**I**) shown in (**G**). Data are presented as mean \pm SD. * $p < 0.05$ vs LoxP-Veh; # $p < 0.05$ vs LoxP-Tor. Scale bars, 100 μm .

ethanol feeding downregulated the mRNA expression of key regulators of de novo lipogenesis (DNL), including *Srebp1c*, *Fasn*, and *Acaca* in the livers of mice compared to pair-fed control mice, and *Depdc5* ablation further reduced their expression (Fig. 6A–C). These findings suggest that DNL is unlikely to contribute to the hepatic lipid accumulation observed in ethanol-fed Depdc5-LKO mice. In addition, hepatic mRNA levels of genes involved in lipid uptake (*Fatp2*, *Fatp5*) and very-low-density lipoprotein (VLDL) secretion (*Mttp*, *Apob*) were not significantly altered in pair- and ethanol-fed LoxP and Depdc5-LKO mice, indicating these two processes may not contribute to the development of alcohol-induced fatty liver in Depdc5-LKO mice (Fig. 6A). Interestingly, the transcription of key genes for fatty acid oxidation, such as *Ppara*, *Cpt1a*, *Acox1*, was reduced after ethanol exposure and *Depdc5* deletion greatly exacerbated the reduction of their expression (Fig. 6A, D, E). As shown in Fig. 6F, the mRNA levels of PPAR α downstream target genes such as *Acadvl*, *Acadm*, *Acadl*, *Cyp4a10*,

Cyp4a14, and *Cyp4a32* were significantly decreased in the livers of pair- and ethanol-fed Depdc5-LKO mice. Consistent with the hypothesis that hepatic *Depdc5* deletion leads to impaired fatty acid oxidation, serum levels of β -hydroxybutyrate, a type of ketone body, were lower in Depdc5-LKO mice than in LoxP mice (Fig. 6G).

RNA-seq was used to determine alterations in the transcriptional profiles of liver tissues from alcohol-treated LoxP and Depdc5-LKO mice. As shown in Fig. S6A, volcano plot results showed the overall differentially expressed genes (DEGs) of the livers between ethanol-fed LoxP and LKO mice. RNA-seq analysis revealed that 335 genes were upregulated and 236 genes were downregulated in Depdc5-LKO livers compared to LoxP livers. KEGG pathway analysis further revealed enrichment of DEGs in multiple pathways (Fig. S6B, C). Consistent with our qPCR data, PPAR signaling pathway was one of the most enriched pathways associated with downregulated DEGs (Fig. S6C).




Fig. 6 Hepatic ablation of *Depdc5* inhibits the expression of PPAR α and its target genes and results in mitochondrial damage. Two–three-month-old LoxP and *Depdc5*-LKO mice were subjected to Gao-Binge ethanol feeding. **A** qPCR analysis of hepatic mRNA expression of genes involved in lipogenesis, fatty acid oxidation, lipid secretion and lipid uptake ($n = 5$ /group). **B**, **C** Western blot (**B**) and quantification (**C**) analyses of hepatic SREBP1 and FASN. **D**, **E** Western blot (**D**) and quantification (**E**) analyses of hepatic PPAR α and CPT1A. **F** qPCR analysis of hepatic mRNA expression of PPAR α target genes ($n = 5$ /group). **G** Serum β -hydroxybutyrate measurements ($n = 6$ /group). **H** Representative electron microscopy images ($\times 2000$ magnification, left panels; $\times 7000$ magnification, middle and right panels) of hepatocytes from Gao-Binge ethanol-treated LoxP and LKO mice. **I**, **J** Numbers of total (**I**) and damaged (**J**) mitochondria were quantified in hepatocytes ($n = 9$ /group) from Gao-Binge ethanol-treated LoxP and LKO mice. Data are presented as mean \pm SD. * $p < 0.05$. In (**A–G**), * $p < 0.05$ vs PF LoxP; # $p < 0.05$ vs AF LoxP. Scale bars, 5 μ m.

Mitochondrial dysfunction plays a dominant role in the pathogenesis of ALD [22]. By analyzing TEM images, we found obvious mitochondrial damage in hepatocytes of ethanol-fed *Depdc5*-LKO mice (Fig. 6H). While total numbers of hepatocyte

mitochondria were only slightly reduced in *Depdc5*-LKO mice, numbers of damaged mitochondria in hepatocytes were markedly increased in *Depdc5*-LKO mice compared to LoxP mice (Fig. 6I, J).




Fig. 7 Fenofibrate treatment ameliorates ethanol-induced hepatic steatosis and inflammation in *Depdc5*-LKO mice. Three-month-old male WT, *LoxP* and *Depdc5*-LKO mice were subjected to Gao-Binge ethanol feeding. **A** qPCR analysis of hepatic mRNA expression of fatty acid oxidation-related genes (*n* = 4/group). **B**, **C** Serum ALT (**B**) and liver TG (**C**) measurements (*n* = 4/group). **D** Representative H&E (upper) and Oil Red O (lower) stained liver sections (200 \times). **E** IHC analysis of 4-HNE, F4/80, and MPO in liver sections (200 \times , *n* = 4/group). **F** Hepatic MDA measurements (*n* = 4/group). **G**, **H** Quantification of F4/80-positive cells (**G**) and MPO-positive cells (**H**) shown in (**E**). Data are presented as mean \pm SD. **p* < 0.05 vs WT-Veh; #*p* < 0.05 vs LoxP-FF. Scale bars, 100 μ m.

fenofibrate treatment stimulated the expression of PPAR α target genes in the livers of both *LoxP* and *Depdc5*-LKO mice compared to vehicle-treated, ethanol-fed WT control mice (Fig. 7A). Gao-Binge ethanol feeding-induced liver injury and steatosis were largely normalized in both *LoxP* and *Depdc5*-LKO mice by fenofibrate administration (Fig. 7B–D). 4-HNE staining and hepatic MDA analysis also showed significant reduction of oxidative stress in both *LoxP* and *Depdc5*-LKO mice after fenofibrate treatment (Fig. 7E, F). IHC staining of F4/80 and MPO revealed that fenofibrate administration markedly reduced the number of macrophages and neutrophils in the liver tissues of both *LoxP* and *Depdc5*-LKO mice fed an ethanol diet (Fig. 7E, G, H).

DISCUSSION

Despite some progress has been made to elucidate the underlying mechanisms of ALD, the pathogenesis of ethanol-induced hepatic steatosis remains elusive. While some reports have indicated that ethanol exposure activates SREBP1c and the lipogenic pathway [24, 25], other studies have shown that ethanol exposure downregulates the expression of *Srebp1c* and lipogenesis-related genes [26, 27]. Furthermore, our current data also revealed that Gao-Binge ethanol feeding reduced hepatic expression of *Srebp1c* and other lipogenic genes in mice. One explanation for the suppression of lipogenic process by ethanol exposure is that ethanol and/or its metabolites impair insulin release and cause insulin resistance, and further inhibit the AKT signaling which is required for the activation of SREBP1c and the lipogenic pathway in the liver [28]. Therefore, the lipogenic pathway may not be a major contributor to the development of ethanol-induced fatty liver. Increased NADH/NAD⁺ ratio caused by ethanol oxidation in hepatocytes favors inhibition of fatty acid β -oxidation in the liver [28]. In addition, ethanol exposure stimulates adipose tissue lipolysis to generate lots of free fatty acids [29]. Therefore, the imbalance of excessive influx of fatty acids mobilized from adipocytes and the suppressed fatty acid oxidation capacity induce excessive fat accumulation in the liver, which is a key mechanism leading to ethanol-induced liver steatosis.

It is well known that mTORC1 activation upregulates SREBP1c expression and promotes lipid synthesis [30, 31]. However, studies of genetically engineered mice with liver-specific knockout of *Tsc1* have demonstrated that activation of mTORC1 in hepatocytes surprisingly protects against diet-induced hepatic steatosis [13, 14]. A recent study and our current data also revealed that mTORC1 hyperactivation caused by *Depdc5* deletion in the liver results in decreased lipid accumulation in mice fed a HFD [15]. Thus, all these results suggest that mTORC1 activation is not sufficient to stimulate SREBP1c and the DNL, and mTORC1-dependent feedback inhibition of AKT signaling underlies the defect in SREBP1c induction. Unexpectedly, we observed an opposite phenotype of lipid metabolism in ethanol-fed *Depdc5*-LKO mice, which hepatic *Depdc5* ablation leads to more severe hepatic steatosis and inflammation in mice exposed to ethanol. Since severe hepatic steatosis develops in *Depdc5*-LKO mice

Fenofibrate administration rescues ethanol-induced liver pathologies in *Depdc5*-LKO mice

To determine whether impaired PPAR α activity contributes to the ethanol-induced liver pathologies observed in *Depdc5*-LKO mice, we then treated ethanol-fed *LoxP* and *Depdc5*-LKO mice with fenofibrate, a clinically used PPAR α agonist [23]. As expected,

administrated with ethanol by two ethanol feeding protocols (Gao-Binge model and LD 5W model), we believe that hepatic mTORC1 activation indeed aggravates ethanol-induced steatosis. However, the question is why sustained activation of mTORC1 in hepatocytes protects liver from diet-induced steatosis but exacerbates hepatic steatosis induced by ethanol exposure? The divergent outcomes are likely attributed to the differences in the pathogenesis between these two fatty liver models. Recent evidence and our findings have shown that sustained activation of mTORC1 does not affect the lipid uptake and VLDL secretion pathways, but notably suppresses the expression of genes involved in both DNL and fatty acid oxidation in the livers of mice treated with either HFD or ethanol [13, 14]. As we know, diet-induced excess lipid accumulation in the liver is largely through the enhancement of DNL pathway which is primarily controlled by SREBP1c [32]. Therefore, suppressed lipogenesis in hepatocytes caused by sustained mTORC1 activation is sufficient to protect the liver from HFD-induced steatosis. However, in the progression of alcoholic liver steatosis, the relative contribution of DNL to alcoholic liver steatosis is less important because ethanol also stimulates adipose tissue lipolysis to release plenty of free fatty acids. Suppressed lipogenesis mediated by mTORC1 hyperactivation is insufficient to prevent excess accumulation of lipids in the liver induced by ethanol exposure. Conversely, mTORC1 activation further inhibits the expression of PPAR α and its target genes, and exacerbates the ethanol-induced fatty acid oxidation defects, thereby leading to alcoholic liver steatosis.

As we reported, sustained mTORC1 activation in hepatocytes suppresses the expression of PPAR α and other β -oxidation-related genes. However, the mechanisms by which mTORC1 hyperactivation inhibits PPAR α expression and activity are still not very clear. Sengupta et al. have demonstrated that mTORC1 regulates PPAR α and ketogenesis via controlling the subcellular localization of NcoR1, co-repressor of PPAR α [33]. Moreover, Kim et al. have revealed that S6K2, a downstream effector of mTORC1, directly interacts with NcoR1 and recruits it to the nucleus to suppress PPAR α activity [34]. But it remains unclear whether S6K2 recruits NcoR1 to suppress PPAR α activity in ethanol-treated hepatocytes.

Accumulating evidence has indicated that persistent suppression of mTORC1 signaling by *Raptor* knockout in the liver or by chronic rapamycin treatment inhibits lipid accumulation but induces inflammation and hepatocellular damage [20]. Consistently, we have also observed that adenovirus-mediated shRNA knockdown of *Raptor* in control mice rescued the alcoholic liver steatosis, but even exacerbated liver injury and inflammation. However, pharmacological inhibition of mTORC1 signaling by Torin 1 treatment (20 mg/kg per day for 5 days) markedly reverses almost all of the ethanol-induced liver abnormalities we observed in *Depdc5*-LKO mice, including liver steatosis, injury, and inflammation. The phenotypic discrepancy may attribute to the different extent of mTORC1 inhibition by these two approaches. Adenoviral shRNA expression system stably induces specific *Raptor* gene silencing in hepatocytes, which results in a persistent mTORC1 suppression. Since the in vivo half-life of Torin 1 is much shorter than that of rapamycin [21], it is reasonable to speculate that Torin 1 (20 mg/kg/day) might inhibit mTORC1 signaling more modestly than shRNA knockdown or even rapamycin, thereby maintaining the hepatic mTORC1 activity in a proper level to avoid liver injury and inflammation caused by persistent mTORC1 suppression. It is worth noting, Torin 1 is an ATP-competitive mTOR inhibitor that directly inhibits both mTORC1 and mTORC2 complexes [35]. Therefore, the differential effects of Ad-shRaptor knockdown and Torin 1 treatment may also be explained by the different inhibitory mechanisms of these two approaches. The exact role mTORC2 signaling plays in ethanol-induced liver steatosis and injury needs to be further studied.

In summary, we demonstrate that hepatocyte-specific *Depdc5* deletion hyperactivates mTORC1 signaling and exacerbates




Fig. 8 A proposed model for the dysregulation DEPDC5-mTORC1 axis in the pathogenesis of alcohol-induced hepatic steatosis. Chronic ethanol consumption leads to KLHL22-mediated degradation of DEPDC5, then activates mTORC1 signaling. Aberrant activation of mTORC1 reduces the expression of PPAR α and its target genes, thereby resulting in alcohol-induced liver steatosis.

ethanol-induced liver steatosis and inflammation. Repressed PPAR α -driven fatty acid oxidation caused by sustained mTORC1 activation contributes to the development of ethanol-induced hepatic steatosis and inflammation. Pharmacological inhibition of mTORC1 signaling by Torin 1 or activation of PPAR α by fenofibrate rescues the ethanol-induced liver abnormalities caused by mTORC1 hyperactivation. Our data provide the first in vivo evidence illustrating the hepatocyte-intrinsic roles of hyperactivation of mTORC1 signaling in regulating the pathogenesis of ALD (Fig. 8).

REFERENCES

- Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology*. 2011;141:1572–85.
- Laplante M, Sabatini DM. mTOR signaling at a glance. *J Cell Sci*. 2009;122:3589–94.
- Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. *Hum Mol Genet*. 2005;14 Spec No. 2:R251–8.
- Baldassari S, Licchetta L, Tinuper P, Bisulli F, Pippucci T. GATOR1 complex: the common genetic actor in focal epilepsies. *J Med Genet*. 2016;53:503–10.
- Dibbens LM, de Vries B, Donatello S, Heron SE, Hodgson BL, Chintawar S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. *Nat Genet*. 2013;45:546–51.
- Ishida S, Picard F, Rudolf G, Noe E, Achaz G, Thomas P, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. *Nat Genet*. 2013;45:552–5.
- Marsan E, Ishida S, Schramm A, Weckhuysen S, Muraca G, Lecas S, et al. *Depdc5* knockout rat: a novel model of mTORopathy. *Neurobiol Dis*. 2016;89:180–9.
- Hughes J, Dawson R, Tea M, McAninch D, Piltz S, Jackson D, et al. Knockout of the epilepsy gene *Depdc5* in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling. *Sci Rep*. 2017;7:12618.

9. Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, et al. DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. *Hepatology*. 2016;63:418–27.
10. Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. *Nat Genet*. 2011;43:797–800.
11. Cho CS, Kowalsky AH, Lee JH. Pathological consequences of hepatic mTORC1 dysregulation. *Genes (Basel)*. 2020;11:896
12. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. *Cell*. 2011;146:408–20.
13. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. *Cell Metab*. 2011;14:21–32.
14. Kenerson HL, Yeh MM, Yeung RS. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. *PLoS ONE*. 2011;6:e18075.
15. Cho CS, Kowalsky AH, Namkoong S, Park SR, Wu S, Kim B, et al. Concurrent activation of growth factor and nutrient arms of mTORC1 induces oxidative liver injury. *Cell Discov*. 2019;5:60.
16. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). *Nat Protoc*. 2013;8:627–37.
17. Xiong X, Yu J, Fan R, Zhang C, Xu L, Sun X, et al. NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice. *PLoS ONE*. 2019;14:e0212523.
18. Chen J, Ou Y, Yang Y, Li W, Xu Y, Xie Y, et al. KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing. *Nature*. 2018;557:585–9.
19. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, et al. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. *Sci Signal*. 2012;5:ra24.
20. Umemura A, Park EJ, Taniguchi K, Lee JH, Shalpour S, Valasek MA, et al. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. *Cell Metab*. 2014;20:133–44.
21. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. *J Biol Chem*. 2012;287:9742–52.
22. Nassir F, Ibdah JA. Role of mitochondria in alcoholic liver disease. *World J Gastroenterol*. 2014;20:2136–42.
23. Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L. Anticancer properties of fenofibrate: a repurposing use. *J Cancer*. 2018;9:1527–37.
24. Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, et al. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. *Hepatology*. 2018;68:496–514.
25. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). *J Biol Chem*. 2002;277:29342–7.
26. Li Q, Xie G, Zhang W, Zhong W, Sun X, Tan X, et al. Dietary nicotinic acid supplementation ameliorates chronic alcohol-induced fatty liver in rats. *Alcohol Clin Exp Res*. 2014;38:1982–92.
27. Yang Z, Tsuchiya H, Zhang Y, Lee S, Liu C, Huang Y, et al. REV-ERB α activates C/EBP homologous protein to control small heterodimer partner-mediated oscillation of alcoholic fatty liver. *Am J Pathol*. 2016;186:2909–20.
28. You M, Arteel GE. Effect of ethanol on lipid metabolism. *J Hepatol*. 2019;70:237–48.
29. Zhao C, Liu Y, Xiao J, Liu L, Chen S, Mohammadi M, et al. FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. *J Lipid Res*. 2015;56:1481–91.
30. Han J, Wang Y. mTORC1 signaling in hepatic lipid metabolism. *Protein Cell*. 2018;9:145–151.
31. Lamming DW, Sabatini DM. A central role for mTOR in lipid homeostasis. *Cell Metab*. 2013;18:465–9.
32. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J Gastroenterol*. 2013;48:434–41.
33. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. *Nature*. 2010;468:1100–4.
34. Kim K, Pyo S, Um SH. S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor α activity in the liver. *Hepatology*. 2012;55:1727–37.
35. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. *J Biol Chem*. 2009;284:8023–32.

ACKNOWLEDGEMENTS

We thank Drs. Zan Huang and Ming Zhao from University of Minnesota Medical School for help with the western blot analysis of human liver samples and Drs. Zhiwei Liu and Fei Zhou from Soochow University for generation of *Depdc5* floxed mice.

AUTHOR CONTRIBUTIONS

L.X. designed, performed the experiments, analyzed the data and wrote the manuscript; X.Z. and Y.X. performed the experiments and analyzed the data; J.M. assisted with generation of ALD mouse models and contributed to tissue samples collection; C.Y. contributed to histological experiments; X.Z. assisted with RNA-seq and TEM studies; G.H. performed RNA-seq data analysis; X.C.D. conceived the study and revised the manuscript; Z.S. provided human specimens and contributed to data collection; X.X. and X.C. conceived the study, designed the experiments, analyzed and interpreted the data, and wrote the manuscript.

FUNDING

This work was supported by grants from National Natural and Science Foundation of China (U1904132, 81670526, 31771541), Program for Science & Technology Innovation Talents in Higher Education of Henan Province (20HASTIT046), Key Scientific Research Project of Universities in Henan (19A180005), Training Program for Excellent Young Teachers in Higher Education of Henan province (2017GGJS110), Ministry of Science and Technology of China (2018YFA0801100).

ETHICS STATEMENT

The study was approved by the Institutional Animal Care and Use Committee of Xinxiang Medical University, China. All animal procedures were performed in accordance with “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health. Control and alcoholic hepatitis human liver samples were obtained under the institutional review board protocol approved by Johns Hopkins University School of Medicine.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41419-021-03980-6>.

Correspondence and requests for materials should be addressed to X.X. or X.C.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021